International Accounts Payable vs Common Stock Shares Outstanding Analysis
IBT Stock | 694.00 8.00 1.17% |
International Biotechnology financial indicator trend analysis is infinitely more than just investigating International Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether International Biotechnology is a good investment. Please check the relationship between International Biotechnology Accounts Payable and its Common Stock Shares Outstanding accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in International Biotechnology Trust. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Accounts Payable vs Common Stock Shares Outstanding
Accounts Payable vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of International Biotechnology Accounts Payable account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between International Biotechnology's Accounts Payable and Common Stock Shares Outstanding is -0.01. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of International Biotechnology Trust, assuming nothing else is changed. The correlation between historical values of International Biotechnology's Accounts Payable and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of International Biotechnology Trust are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Accounts Payable i.e., International Biotechnology's Accounts Payable and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | -0.01 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Accounts Payable
An accounting item on the balance sheet that represents International Biotechnology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of International Biotechnology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from International Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into International Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in International Biotechnology Trust. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. As of November 26, 2024, Selling General Administrative is expected to decline to about 1.1 M. In addition to that, Tax Provision is expected to decline to about 129.3 K
International Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
International Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
International Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 302.7M | 347.8M | 326.9M | 304.9M | 308.2M | 204.7M | |
Total Stockholder Equity | 283.9M | 323.8M | 284.9M | 270.3M | 282.3M | 193.5M | |
Cash | 886K | 324K | 1.6M | 0.0 | 10.4M | 11.0M | |
Other Assets | 116K | 97K | 146K | 248K | 308.2M | 323.6M | |
Total Liab | 18.8M | 24.1M | 42.0M | 34.6M | 25.9M | 27.2M | |
Accounts Payable | 715K | 1.6M | 1.2M | 143K | 1.9M | 1.8M | |
Other Current Liab | (18.8M) | (23.5M) | (41.2M) | (32.6M) | (1.9M) | (2.0M) | |
Total Current Liabilities | 124K | 2.2M | 1.2M | 143K | 164.5K | 156.2K | |
Net Debt | 17.8M | 20.3M | 40.0M | 32.5M | 12.4M | 8.8M | |
Retained Earnings | 221.6M | 252.1M | 213.2M | 198.6M | (54.0M) | (51.3M) | |
Non Current Assets Total | 302.2M | 345.3M | 313.4M | 301.9M | 297.5M | 210.9M | |
Non Currrent Assets Other | (302.2M) | (345.3M) | (313.4M) | (301.9M) | (297.5M) | (312.4M) | |
Cash And Short Term Investments | 886K | 324K | 1.6M | 10.4M | 12.0M | 12.6M | |
Net Receivables | 45K | 845K | 13.3M | 2.7M | 99K | 94.1K | |
Common Stock Shares Outstanding | 38.5M | 40.5M | 41.1M | 40.6M | 38.2M | 38.0M | |
Liabilities And Stockholders Equity | 302.7M | 347.8M | 326.9M | 304.9M | 308.2M | 218.2M | |
Non Current Liabilities Total | 18.1M | 21.9M | 1.2M | 32.5M | 37.3M | 39.2M | |
Other Stockholder Equity | 229.2M | (242.2M) | (265.9M) | 61.4M | 29.9M | 23.3M | |
Total Current Assets | 369K | 2.4M | 13.3M | 2.7M | 10.6M | 11.2M | |
Other Current Assets | 163.0K | 141K | 214K | 283K | (10.5M) | (10.0M) | |
Net Tangible Assets | 239.6M | 283.9M | 323.8M | 284.9M | 327.6M | 282.9M | |
Long Term Investments | 302.2M | 345.3M | 313.4M | 301.9M | 297.5M | 302.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in International Stock
Balance Sheet is a snapshot of the financial position of International Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. International Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of International Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which International currently owns. An asset can also be divided into two categories, current and non-current.